<?xml version="1.0" encoding="UTF-8"?>
<ref id="B24">
 <label>24.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Hussaarts</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Mühlebach</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Shah</surname>
    <given-names>VP</given-names>
   </name>
   <name>
    <surname>McNeil</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Borchard</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Flühmann</surname>
    <given-names>B</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Equivalence of complex drug products: advances in and challenges for current regulatory frameworks</article-title>. 
  <source>Ann N Y Acad Sci</source>. (
  <year>2017</year>) 
  <volume>1407</volume>:
  <fpage>39</fpage>–
  <lpage>49</lpage>. 
  <pub-id pub-id-type="doi">10.1111/nyas.13347</pub-id>
  <?supplied-pmid 28445611?>
  <pub-id pub-id-type="pmid">28445611</pub-id>
 </mixed-citation>
</ref>
